Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Feb 12, 2023 7:28pm
213 Views
Post# 35282344

RE:RE:A little decision analysis

RE:RE:A little decision analysis

I agree on the " values" of the last corporation updates.
Specifically the Pancreatic cancer results. They afterall were discussed in deatai with the Kol key opinion leaders, telecfonference.
Although quite medical in context, quite well explained & very enthusiastic.
Then can A.N. Update giving " further encouraging signs of Pelareorep as a cancer co- therapy"
now"................
All politics, speculation & even business models aside.
The only reason ONC was incorporated, was to get Pela approved for market as a cancer treatment.
Once again back to the science. Does it work or not.
If it does, the business end will fall naturally into place.
LIF not, no discussions further.

So?
Based on existing data & date points, all arrows point to June as the latest, with mid March being the earliest as to revealing Aware-1, bracelet & the very silent Pancreatic cancer Goblet & additional G.I. Cancers.
With an almost instant FDA fast track designation for Pelareorep ( pancreatic cancer) alongside Roche Tecentriq; I view that as very positive scientific evidence.
The idea that Onc is a scam is childish nonsense. There are too many eyes on not only Onc as a company, but the product itself. Pelareorep is presently in no fewer than a dozen locations, with mutiple.PHDs analyzing, reviewing etc etc.
SOLTI for example. Global leader in breast cancer research. They not only ran the Aware-1 trial, but have a representative on Onc scientific advisory board.
Have a great week all.
 

<< Previous
Bullboard Posts
Next >>